Antineovascular agents in the treatment of eye diseases

Current Pharmaceutical Design

Volumn 12, Issue 21, 2006, Pages 2645-2660

  Eichler, Wolfram ^a   Yafai, Yousef ^a   Wiedemann, Peter ^a   Fengler, Dörte ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Age related macular degeneration; Angiogenesis; Diabetic retinopathy; Pharmacotherapy; Retina

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ANGIOSTATIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPTOPRIL; COMBRETASTATIN; CORTICOSTEROID DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOSTATIN; ENDOTHELIAL CELL GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; LISINOPRIL; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGAPTANIB; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C INHIBITOR; RANIBIZUMAB; RUBOXISTAURIN; SOMATOSTATIN DERIVATIVE; THALIDOMIDE; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VATALANIB;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIABETIC RETINOPATHY; DOSE RESPONSE; DROWSINESS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; EYE DISEASE; HUMAN; NONHUMAN; PATHOGENESIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; SUBRETINAL NEOVASCULARIZATION; TERATOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANIMALS; EYE DISEASES; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33745763138     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777698729     Document Type: Review

References (250)

1. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998; 43: 245-69.
2. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
3. Bossi E, Koerner F. Retinopathy of prematurity. Intensive Care Med 1995; 21: 241-6.
4. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis 1999; 5: 34.
5. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48: 257-93.
6. Muñoz-Chápuli R, Quesada AR, Ángel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 2004; 61: 2224-43.
7. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001; 489: 270-6.
8. Folkman J. Angiogenesis in cancer, vascular, rheumatoid, and other diseases. Nat Med 1995; 1: 27-31.
9. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8: 349-57.
10. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med 2002; 8: 330-4.
11. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization Proc Natl Acad Sci USA 1995; 92: 905-9.
12. Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr Eye Res 1999; 18: 203-13.
13. Yi X, Ogata N, Komada M, Yamamoto C, Takahashi K, Omori K, et al. Vascular endothelial growth factor expression in choroidal neovascularization in rats. Graefe's Arch Clin Exp Ophthalmol 1997; 235: 313-19.
14. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338-46.
15. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/ vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146: 1029-39.
16. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538-44.
17. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995; 15: 4738-47.
18. Shima DT, Adamis AP, Ferrara N, Yeo KT, Yeo TK, Allende R, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995; 1: 182-93.
19. Eichler W, Kuhrt H, Hoffmann S, Wiedemann P, Reichenbach A. VEGF release by retinal glia depends on both oxygen and glucose supply. Neuroreport 2000; 11: 3533-7.
20. Michaelson M. The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948; 68: 137-80.
21. Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72: 638-45.
22. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-8.
23. Ashton, N. Retinal vascularization in health and disease. Am J Ophthalmol 1957; 44: 7-17.
24. Donahue ML, Phelps DL, Watkins RH, LoMonaco MB, Horowitz S. Retinal vascular endothelial growth factor (VEGF) mRNA expression is altered in relation to neovascularization in oxygen induced retinopathy. Curr Eye Res 1996, 15: 175-84.
25. Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
26. Aiello LP, Avery RP, Arrigg PG, Keyt BA, Jampel HD, Shan ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
27. Adamis AP, Miller JW, Bernal MT, D'Amico DJ, Folkman J, Yeo TK, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy, Am J Ophthalmol 1994; 118: 445-50.
28. Miller JW, Adamis A, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev 1997; 13: 37-50.
29. Ishida S, Usui T, Yamashiro Y, Kaji Y, Amano S, Ogura Y, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198: 483-9.
30. Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-62.
31. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49: 568-81.
32. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci 2003; 28: 488-9.
33. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457-61.
34. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LE. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996; 93: 4851-6.
35. Garrett KL, Shen WY, Rakoczy PE. In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye. J Gene Med 2001; 3: 373-83.
36. Honda M, Sakamoto T, Ishibashi T, Inomata H, Ueno H. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 2000; 7: 978-85.
37. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9.
38. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
39. Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996; 114: 66-71.
40. Available from http://www.macular.org/news/lucentis.html. Accessed 23 December 2005.
41. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization, Am J Pathol 2000; 156: 697-707.
42. Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22: 143-52.
43. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110: 979-6.
44. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
45. Eyetech Study Group. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110: 979-86.
46. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
47. Mathura JR Jr, Jafari N, Chang JT, Hackett SF, Wahlin KJ, Della NG, et al. Bone morphogenetic proteins-2 and -4: negative growth regulators in adult retinal pigmented epithelium. Invest Ophthalmol Vis Sci 2000; 41: 592-600.
48. Eichler W, Yafai Y, Kuhrt H, Hoffmann, S, Wiedemann, P. Reichenbach, A. Hypoxia: modulation of endothelial cell proliferation by soluble factors released by retinal cells. Neuroreport 2001; 12: 4103-8.
49. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-8.
50. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999; 274: 11721-6.
51. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-85.
52. Lucas R, Holmgren L, Garcia I, Jimenez B, Mandriota SJ, Borlat F, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998; 92: 4730-41.
53. Lai CC, Wu WC, Chen SL, Xiao X, Tsai TC, Huan SJ, et al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 2001; 42: 2401-7.
54. Mori K, Ando A, Gehlbach P, Nesbitt D, Takahashi K, Goldsteen D, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001; 159: 313-20.
55. Tombran-Tink J, Barnstable CJ. Therapeutic prospects for PEDF: more than a promising angiogenesis inhibitor. Trends Mol Med 2003; 9: 244-50.
56. Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res 2004; 23: 561-77.
57. Becerra SP, Sagasti A, Spinella P, Notario V. Pigment epithelium derived factor behaves like a noninhibitory serpin. Neurotropic activity does not require the serpin reactive loop. J Biol Chem 1995; 270: 24992-9.
58. Maik-Rachline G, Shaltiel S, Seger R. Extracellular phosphorylation converts pigment epithelium-derived factor from a neurotrophic to an antiangiogenic factor. Blood 2005; 105: 670-8.
59. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-9.
60. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA 2001; 98: 2593-7.
61. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285: 245-8.
62. Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 2004; 101: 6605-10.
63. Mori K, Gehlbach P, Ando A, McVey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002; 43: 2428-34.
64. Apte RS, Barreiro RA, Duh E, Volpert O, Ferguson TA. Stimulation of neovascularization by the anti-angiogenic factor PEDF. Invest Ophthalmol Vis Sci 2004; 45: 4491-7.
65. Spranger J, Osterhoff M, Reimann M, Mohlig M, Ristow M, Francis MK, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001; 50: 2641-5.
66. Ogata, N, Tombran-Tink J, Nishikawa M, Nishimura T, Mitsuma Y, Sakamoto T, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 2001; 132: 378-82.
67. Holekamp NM, Bouck NP, Volpert OV. Pigment epithelium derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am J Ophthalmol 2002; 134: 220-27.
68. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002; 134: 348-53.
69. Duh EJ, Yang HS, Haller JA, De Juan E, Humayun MS, Gehlbach P, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol 2004; 137: 668-74.
70. Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, et al. Clinical protocol: an open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12: 2029-32.
71. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med 2001; 18: 945-59.
72. Koya, D, King, GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47: 859-66.
73. Park JY, Ha SW, King GL. The role of protein kinase C activation in the pathogenesis of diabetic vascular complications. Perit Dial Int 1999; 2: 222-7.
74. Donnelly R, Idris I, Forrester JV. Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational research. Br J Ophthalmol 2004; 88: 145-51.
75. Williams B, Gallacher B, Patel H, Orme C. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997; 46: 1497-503.
76. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018-26.
77. Suzuma K, Takahara N, Suzuma I, Isshiki K, Ueki K, Leitges M, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci USA 2002; 99: 721-6.
78. Aiello LP, Bursell SE, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80.
79. Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997; 64: 505-17.
80. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH III, Neel DA, et al. (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4, 9:16,21-dimetheno-1H,13H-dibenzo [e,k]pyrrolo[3,4-h] [1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C-β. J Med Chem 1996; 39: 2664-71.
81. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC beta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39: 171-9.
82. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 3: 272: 728-31.
83. Bursell SE, Takagi C, Clermont AC, Takagi H, Mori F, Ishii H, et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997; 38: 2711-20.
84. Aiello LP, Bursell S, Devries T, Alatorre C, King GL, Ways K. Protein kinase C β selective inhibitor LY333531 ameliorates abnormal retinal hemodynamics in patients with diabetes. Diabetes 1999, 48: A19.
85. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002; 86: 363-5.
86. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450-2.
87. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy Semin 1999; 14: 233-9.
88. Chibber R, Ben-Mahmud BM, Mann GE, Zhang JJ, Kohner EM. Protein kinase C beta2-dependent phosphorylation of core 2 G1cNAc-T promotes leukocyte-endothelial cell adhesion: a mechanism underlying capillary occlusion in diabetic retinopathy. Diabetes 2003; 52: 1519-27.
89. Nonaka A, Kiryu J, Tsujikawa A, Yamashiro K, Miyamoto K, Nishiwaki H, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 2000; 41: 2702-6.
90. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1995; 97: 2883-90.
91. Ceolotto G, Gallo A, Miola M, Sartori M, Trevisan R, Del Prato S, et al. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 1999; 48: 1316-22.
92. Aiello LP, Davis MD, Sheetz MJ. The PKC Inhibitor Diabetic Retinopathy Study Group. Design, baseline patient characteristics and high prevalence of clinically significant macular edema (CSME) in patients with moderately severe to very severe nonproliferative diabetic retinopathy (NPDR) in the Protein Kinase C Diabetic Retinopathy Study (PKC-DRS). Diabetes 2002; 51 (suppl 2): A209.
93. Wilkinson-Berka JL, Kelly DJ, Gilbert RE. The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. J Vase Res 2001; 38: 527-35.
94. Funatsu H, Yamashita H. Pathogenesis of diabetic retinopathy and the renin-angiotensin system. Ophthalmic Physiol Opt 2003; 23: 495-501.
95. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. Effect of Lisinopril on progression of retinopathy in normotensive people with type I diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
96. The EUCLID Study Group. Randmised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787-92.
97. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema. Pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-64
98. Nagai N, Noda K, Urano T, Kubota Y, Shinoda H, Koto T, et al. Selective suppression of pathologic, but not physiologic, retinal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Via Sci 2005; 46: 1078-84.
99. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1998; 1401: 187-94.
100. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998; 82: 619-28.
101. Higgins RD, Yan Y, Geng Y, Sharma J, Barr SM. Captopril and vascular endothelial growth factor in a mouse model of retinopathy. Curr Eye Res 2003; 27: 123-9.
102. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671-9.
103. Tadesse M, Yan Y, Yossuck P, Higgins RD. Captopril improves retinal neovascularization via endothelin-1. Invest Ophthalmol Vis Sci 2001; 42: 1867-72.
104. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, et al. Retinal neovascularization is prevented by blockade of the rennin-angiotensin system. Hypertension 2000; 36: 1099-104.
105. Lonchampt M, Pennel L, Duhault J. Hyperoxia/normoxia-driven retinal angiogenesis in mice: a role for angiotensin II. Invest Ophthalmol Vis Sci 2001; 42: 429-32.
106. Nagisa Y, Shintani A, Nakagawa S. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. Diabetologia 2001; 44: 883-8.
107. Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, de Vries-Knoppert WA, van Hinsbergh VW, Tangelder GJ. ACE inhibiting therapy is associated with lower vitreous VEGF concentrations in patients with PDR. Diabetologia 2002; 45: 203-9.
108. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Brit Med J 1998; 317: 713-72.
109. Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. Eur J Pharmacol 2004; 498: 275-8.
110. Yamada M, Kawai M, Kawai Y, Mashima Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res 1999; 19: 300-4.
111. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Mol Med 2003; 9: 73-8.
112. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 2002; 62: 625-31.
113. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94:2036-44.
114. Ziche M, Jones J, Gullino PM. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982; 69: 475-82.
115. Form DM, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983; 172: 214-8.
116. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999; 59: 4574-7.
117. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10: 3331-48.
118. Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol 2004; 287: 735-41.
119. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002; 16: 438-40.
120. Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. Invest Ophthalmol Via Sci 1998; 39: 581-91.
121. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
122. Murphy JF, Steele C, Belton O, Fitzgerald DJ. Induction of cyclooxygenase-1 and -2 modulates angiogenic responses to engagement of alphav beta3. Br J Haematol 2003; 121: 157-64.
123. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, Dey SK, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003; 63: 906-11.
124. Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000, 60: 4705-8.
125. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000; 7: 1163-70.
126. Yu DY, Cringle SJ. Oxygen distribution and consumption within the retina in vascularised and avascular retinas and in animal models of retinal disease. Prog Retin Eye Res 2001; 20: 175-208.
127. Rohan RM, Fernandez A, Udagawa T, Yuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J 2000; 14: 871-6.
128. Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene 2003; 22: 6537-48.
129. Arber N, Levin B. Chemoprevention of colorectal cancer: ready for routine use? Recent Results Cancer Res 2005; 166: 213-30.
130. Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002; 21: 193-201.
131. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology 1991; 98 (suppl): 757-65.
132. Hallak A, Alon-Baron L, Shamir R, Moshkowitz; M, Bulvik B, Brazowski E, et al. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003; 48: 1998-2002.
133. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004; 23: 63-75.
134. Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol 2004; 31: 12-21.
135. Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finley J, Thompson HW, et al. Coordinate activation of HIF-1 and NF-kappaB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci 2003; 44: 4163-70.
136. Mezentsev A, Sets F, Dunn MW, Ono N, Falck JR, Laniado-Schwartzman M. Eicosanoid regulation of vascular endothelial growth factor expression and angiogenesis in microvessel endothelial cells. J Biol Chem 2002; 277: 18670-6.
137. Castro MR, Lutz D, Edelman JL. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 2004, 79: 275-85.
138. Sennlaub F, Valamanesh F, Vazquez-Tello A, El-Asrar AM, Chec-chin D, Brault S, et al. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation 2003; 108: 198-204.
139. Kern TS, Engerman RL. Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes 2001; 50: 1636-42.
140. Nandgaonkar BN, Rotschild T, Yu K, Higgins RD. Indomethacin improves oxygen-induced retinopathy in the mouse. Pediatr Res 1999; 46:184-8.
141. Sharma J, Barr SM, Geng Y, Yon Y, Higgins RD. Ibuprofen improves oxygen-induced retinopathy in a mouse model. Curr Eye Res 2003; 27: 309-14.
142. Wilkinson-Berka JL, Alousis NS, Kelly DJ, Gilbert RE. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2003; 44: 974-9.
143. Avila-Vazquez M, Maffrand I, Sosa M, Franco M, De Alvarez BV, Cafferata ML, et al. Treatment of Retinopathy of Prematurity with topical ketorolac tromethamine: a preliminary study. BMC Pediatr 2004; 4: 15.
144. Takahashi K, Saishin Y, Saishin Y, Mori K, Ando A, Yamamoto S, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003; 44: 409-15.
145. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000; 24: 371-84.
146. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000; 24: 357-70.
147. Voigt M, Kralinger M, Kieselbach G, Chapon P, Anagnoste S, Hayden B, et al. Ocular aspirin distribution: a comparison of intravenous, topical, and coulomb-controlled iontophoresis administration. Invest Ophthalmol Vis Sci 2002; 43: 3299-306.
148. Calvo P, Alonso MJ, Vila-Jato JL, Robinson JR. Improved ocular bioavailability of indomethacin by novel ocular drug carriers. J Pharm Pharmacol 1996; 48: 1147-52.
149. Balasubramaniam J, Kant S, Pandit JK. In vitro and in vivo evaluation of the Gelrite gellan gum-based ocular delivery system for in-domethacin. Acta Pharm 2003; 53: 251-61.
150. Chetoni P, Panichi L, Burgalassi S, Benelli U, Saettone MF. Pharmacokinetics and anti-inflammatory activity in rabbits of a novel indomethacin ophthalmic solution. J Ocul Pharmacol Ther 2000; 16: 363-72.
151. Folkman J, Ingber D. Angiostatic steroids. Am Surg 1987; 206: 374-83.
152. Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: a pilot study. Aust NZ J Ophthalmol 1995; 23: 293-8.
153. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust NZ J Ophthalmol 1998; 26: 277-81.
154. Danis RP, Bingaman DP, Yang Y, Ladd B. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology 1996; 103: 2099-104.
155. Ishibashi T, Miki K, Sorgente N, Patterson R, Ryan SJ. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985, 103: 708-11.
156. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, et al. Intravitreous triamcinolone for refractory diabetic macular edema. Ophthalmology 2002; 109: 920-7.
157. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Preliminary results of a prospective controlled trial. Ophthalmology 2004; 111: 218-25.
158. Penfold PL, Wen L, Madigan MC, King NJ, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest Ophthalmol Vis Sci 2002; 43: 3125-30.
159. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreous steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992; 110: 1155-9.
160. Jonas JB, Kreissig I, Degenring RF, Kamppeter BA. Repeated intravitreal injection of triamcinolone acetonide for diffuse diabetic macular oedema. Br J Ophthalmol 2005; 89: 122.
161. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20: 244-250.
162. Jonas JB, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R. Intravitreal triamcinolone acetonide for exudative age-related macular degeneration. Br J Ophthalmol 2003; 87: 462-468.
163. Jonas JB, Kreissig I, Degenring RF. Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age related macular degeneration. Br J Ophthalmol 2004; 86: 1557-62.
164. Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, et al. Randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003; 121: 667-73.
165. Penn JS, Rajaratnam VS, Collier RJ, Clark AF. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 2001; 42: 283-90.
166. Miller JW, Lane AM. Anecortave acetate: Author reply. Ophthalmology 2004; 111: 2316-7.
167. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, et al. Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003; 110: 2372-83.
168. Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117: 508-15.
169. Rohan RM, Fernandez A, Udagawa T, Yuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J 2000; 14: 871-6.
170. Fujita Y, Asami Y, Tanaka Y, Akita M, Merker HJ. Anti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aorta. Histochem Cell Biol 2004, 122: 27-33.
171. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 2001; 7: 3349-55.
172. Sleijfer S, Kruit WH, Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 2004; 40: 2377-82.
173. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
174. Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Am Oncol 2004; 15: 1151-60.
175. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D. Tbalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 1999; 43: 109-14.
176. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-5.
177. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-8.
178. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volcker HE. Tbalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Arch Clin Exp Ophthalmol 1998; 236: 461-6.
179. Joussen AM, Germann T, Kirchhof B. Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. Graefe's Arch Clin Exp Ophthalmol 1999; 237: 952-61.
180. Perino S, Contino-Pepin C, Satchi-Fainaro R, Butterfield C, Pucci B. Inhibition of angiogenesis by THAM-derived cotelomers endowed with thalidomide moieties. Bioorg Med Chem Lett 2004; 14: 421-5.
181. Abbas A, Khan B, Feroze AH, Hyman GF. Thalidomide prevents donor corneal graft neovascularization in an alkali burn model of corneal angiogenesis. J Pak Med Assoc 2002; 52: 476-82.
182. Bosco AA, Lerario AC, Santos RF, Wajchenberg BL. Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats. Diabetologia 2003; 46: 1669-75.
183. Franks ME, Macpherson GR, Figg WD. Thalidomide. Lancet 2004; 363:1802-11.
184. Available from http://drgeene.mediwire.com/main/ Default.aspx?P=Content&ArticleID=3208. Accessed 23 December 2005.
185. Hynes RO. Integrins: versatility, modulation, and signalling in cell adhesion. Cell 1992; 69: 11-25.
186. 5 in ocular neovascular diseases. Proc, Natl Acad Sci USA 1996; 93: 9764-9.
187. 3 inhibit retinal neovascularization in a murine model. Lab Invest 1996; 75: 563-73.
188. v integrins. Science 1995; 270: 1500-2.
189. 3 for angiogenesis. Science 1994; 264: 569-71.
190. β3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995; 96: 1815-22.
191. Brower V. Tumor angiogenesis-new drugs on the block. Nat Biotechnol 1999; 17: 963-8.
192. Hammes HP, Brownlee M, Jonczyk A, Sutter A, Preissner KT. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med 1996; 2: 529-33.
193. Yasukawa T, Hoffmann S, Eichler W, Friedrichs, U, Wang YS, Wiedemann P. Inhibition of experimental choroidal neovascularization in rats by an alpha(v)-integrin antagonist. Curr Eye Res 2004; 28: 359-66.
194. 3 antagonist J Clin Invest 1999; 103: 47-54.
195. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994; 79:1157-64.
196. Stetler-Stevenson WG. MMP in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999; 103: 1237-41.
197. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multi-functional contributors to tumor progression. Mol Med Today 2000; 6: 149-56.
198. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491-4.
199. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157: 351-8.
200. Anand-Apte B, Pepper MS, Voest E, Montesano R, Olsen B, Murphy G, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinases-3. Invest Ophthalmol Vis Sci 1997; 38: 817-23.
201. Benelli R, Adatia R, Ensoli B, Stetler-Stevenson WG, Santi L, Albini A. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol Res 1994; 6: 251-7.
202. Hiraoka N, Allen E, Appel IJ, Gyetko MR, Weiss SJ. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95:365-77.
203. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, et al. MMP-9/gelatinase B is a key regulator of growth plate angio-genesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 411-22.
204. Itoh T, Tonioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-51.
205. Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000; 151: 879-89.
206. Lambert V, Wielockx B, Munaut C, Galopin C, Jost M, Itoh T, et al. MMP-2 and MMP9 synergize in promoting choroidal neovascularization. FASEB J 2003; 17: 2290-2.
207. Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A. Matrix metalloprotemases and metalloprotemase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998; 39: 2194-200.
208. Jin M, Kashiwagi K, Iizuka Y, Tanaka Y, Imai M, Tsukahara S. Matrix metalloprotemases in human diabetic and nondiabetic vitreous. Retina 2001; 21: 28:33.
209. DeClerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994; 30: 2170-80.
210. Montgomery AM, Mueller BM, Reisfeld RA, Taylor SM, De-Clerck YA. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994; 54: 5467-73
211. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994; 86: 299-304.
212. Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF, et al. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994; 54: 4791-7.
213. Schultz RM, Silberman S, Persky B, Bajkowski AS, Carmichael DF. Inhibition by human recombinant tissue inhibitor of metallo proteinases of human amnion invasion and lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988; 48: 5539-45.
214. Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990; 82: 589-95.
215. Khokha R. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989; 243: 947-50.
216. Reich R, Stratford B, Klein K, Martin GR, Mueller RA, Fuller GC. Inhibitors of collagenase IV and cell adhesion reduce the invasive activity of malignant tumour cells. Ciba Found Symp 1988; 141: 193-210.
217. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
218. Brown PD. Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 2000; 9: 2167-77.
219. Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 1999; 5: 1905-17.
220. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999; 878: 236-70.
221. Ozerdem U, Mach-Hofacre B, Varki N, Folberg R, Mueller AJ, Ochabski R, et al. The effect of prinomastat (AG2240), a synthetic inhibitor of matrix metalloproteinases, on uveal melanoma rabbit model. Curr Eye Res 2002; 24: 86-91.
222. Cheng L, Rivero ME, Garcia CR, McDermott CD, Keefe KS, Wiley CA, et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocul Pharmacol Ther 2001; 17: 295-304.
223. Garcia C, Bartsch DU, Rivero ME, Hagedorn M, McDermott CD, Bergeron-Lynn G, et al. Efficacy of prinomastat (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr Eye Res 2002; 24: 33-8.
224. Das A, McLamore A, Song W, McGuire PG. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1999; 117: 498-503.
225. Blodi BA. Effects of Prinomastat (AG3340), an angiogenesis in-hibitor, in patients with subfoveal choroidal neovascularization associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2001; 42: S311.
226. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276: 1706-9.
227. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Aboufriekha M, Guy J. Insulin-like growth factor I acts as an angiogenic agent in rabbit cornea and retina: comparative studies with basic fibroblast growth factor. Diabetologia 1993; 36: 282-91.
228. Demir T, Celiker UO, Kukner A, Mogulkoc R, Celebi S, Celiker H. Effects of Octreotide on experimental corneal neovascularization. Acta Ophthalmol Scand 1999; 77: 386-90.
229. Danesi R, Agen C, Benelli U, Paolo AD, Nardini D, Bocci G, et al. Inhibition of experimental angiogenesis by the Somatostatin analogue octreotide acetate (SMS 201-995). Clin Cancer Res 1997; 3: 265-72.
230. Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, Kliffen M, Baarsma GS, van Hagen PM, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2000; 41: 2329-35.
231. Grant MB, Caballero S, Millard WJ. Inhibition of IGF-I and bFGF stimulated growth of human retinal endothelial cells by the somatostatin analogue, octreotide: a potential treatment for ocular neovascularization. Regul Pept 1993; 48: 267-78.
232. Woltering EA. Development of targeted somatostatin-based antiangiogenic therapy: a review and future perspectives. Cancer Biother Radiopharm 2003; 18: 601-9.
233. Spraul CW, Baldysiak-Figiel A, Lang GK, Lang GE. Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefe's Arch Clin Exp Ophthalmol 2002; 240: 227-31.
234. Mallet B, Vialettes B, Haroche S, Escoffier P, Gastaut P, Taubert JP, et al. Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995. Diabete Metab 1992; 18: 438-44.
235. Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy. Diabetes Care 2000; 23: 504-9.
236. McCombe M, Lightman S, Eckland DJ, Hamilton AM, Lightman SL. Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. Eye 1991; 5: 569-75.
237. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001; 108: 2266-72.
238. Cirla A, Mann J. Combretastatins: from natural products to drug discovery. Nat Prod Rep 2003; 20: 558-64.
239. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-27.
240. Griggs J, Skepper JN, Smith GA, Brindle KM, Metcalfe JC, Hesketh R. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am J Pathol 2002; 160: 1097-103.
241. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, et al. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. J Clin Invest 2005; 115: 2992-3006.
242. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61: 6413-22.
243. Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003; 44: 3650-5.
244. Simoni D, Grisolia G, Giannini G, Roberti M, Rondanin R, Piccagli L, et al. Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J Med Chem 2005; 48: 723-36.
245. Ahmed B, Van Eijk LI, Bouma-Ter Steege JC, Van Der Schaft DW, Van Esch AM, Joosten-Achjanie SR, et al. Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent an-giogenesis inhibitory activity. Int J Cancer 2003; 105: 20-5.
246. Available from http://www.biotechnologyhealthcare.com/Daily/ DailyDetail.cfm?chosen=436. Accessed 23 December 2005.
247. Available from http://www.mdsupport.org/library/anti-angio.html. Accessed 23 December 2005.
248. Mousa SA, Mousa AS. Angiogenesis inhibitors: current & future directions. Curr Pharm Des 2004; 10(1): 1-9.
249. Wegewitz U, Gohring I, Spranger J. Novel approaches in the treatment of angiogenic eye disease. Curr Pharm Des 2005; 11(18): 2311-30.
250. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10(27): 3331-48.